Rosemary-derived compound shows promise in Alzheimer's treatment

Recent scientific research highlights the potential of a rosemary-derived compound in combating Alzheimer's disease. The compound, known as diAcCA, is a stabilized form of carnosic acid—a substance naturally found in rosemary and sage renowned for its antioxidant and anti-inflammatory properties. Traditional carnosic acid faces limitations due to rapid breakdown, but diAcCA remains stable and effectively converts into active form within the body. In a 2025 study published in the journal Antioxidants, experiments on mice genetically modified to develop Alzheimer’s showed significant cognitive improvements after treatment with diAcCA. The mice exhibited increased synaptic connections, crucial for learning and memory, along with reduced brain inflammation. Notably, the compound targets inflamed areas selectively, potentially minimizing side effects. The research team, led by Dr. Stuart Lipton, noted that diAcCA also decreased levels of Alzheimer’s-associated proteins such as amyloid-β and phosphorylated tau. Its ability to cross the blood-brain barrier and activate protective genetic pathways suggests promising therapeutic applications. Given that carnosic acid is recognized as saf...